IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Guillermo MOR

Application Serial No.: not yet assigned

Application Filed: concurrently

For: APOPTOSIS-BASED EVALUATION OF CHEMOSENSITIVITY IN CANCER

PATIENTS

U.S. Patent and Trademark Office Customer Service Window Mail Stop New Application Randolph Building 401 Dulany Street Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Appl §§1.9

icant(s)	hereby submits the following information in conformance with 37 C.F.R.			
97 and 1	.98. · ··			
[X]	Pursuant to 37 C.F.R. §1.98, a copy of each non-US patent document cited in the attached Form PTO/SB/08 is enclosed.			
[]	No copies of the publications listed on the attached Form PTO/SB/0 are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office prior Application Serial No to which the above-identified application claims priority under 35 U.S.C. §120.			
[]	No copies of any U.S. patents or U.S. patent application publication listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98.			
0	Publication(s) listed on the attached Form PTO/SB/08 were cited in a foreign search or examination report corresponding to application serial no and mailed on			
[]	Enclosed is a copy of a non-English publication(s) Pursuant to \$609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).			
[]	Enclosed is a copy of a non-English publication(s) English language publication (copy enclosed) claims priority from this non-			

English publication.

		an English translation is not available.				
	[]		ed is an English I the attached Form l		non-English	publication(s)
	[]	Enclose	ed is a copy of pendi	ing patent Appl	cation Serial N	No
This Information Disclosure Statement is filed within any one of the following time periods:				f the following		
		[]	within three mont application other that			
		[X]	within three months as set forth in 37 C.		•	
		[]	before the mailing of	date of a first of	fice action on t	the merits; or
		[]	before the mailing request for continue			_
	It is r	espectf	ully requested that	the Examiner	consider the	e above-noted
information and return an initialed copy of the attached Form PTO/SB/08 to the						
unders	igned.					
Dated:	Dated: May 22, 2006 Respectfully submitted, COOLEY GODWARD LLP			-		
COOLEY GODWARD LLP ATTN: Patent Group						

By:

Heather M. Boussios

Reg. No. 52,704

Enclosed is an explanation of non-English publication(s) ___ for which

[]

The Bowen Building 875 15th Street NW, Suite 800 Washington, DC 20005-2221

Tel: (202) 842-7800

Fax: (202) 842-7899

Please type a plus sign (+) inside this box ->

IAPZOREC' DCT/PTO 22 MAY 2006

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO		Complete if Known		
		Application Number	not yet assigned and a said a	
INFORMATION DISCLOSURE		Filing Date	concurrently	
STATEMENT BY APPLICANT (use as many sheets as necessary)		First Named Inventor	Guillermo Mor	
		Group Art Unit	not yet assigned	
		Examiner Name	not yet assigned	
Sheet	l of 1	Attorney Docket Number	YALE-106/00US	

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/C.Y./	1	Ofir et al., 2002, Taxol-Induced Apoptosis in Human SKOV3 Ovarian and MCF7 Breast Carcinoma Cells in Caspase-3 and Caspase-9 Independent, Cell Death and Differentiation, 9, 636-642.	
/C.Y./	2	Kolfschoten <i>et al.</i> , 2002, Time-Dependent Changes in Factors Involved in the Apoptosis Process in Human Ovarian Cancer Cells as a Response to Cisplatin, Gynecologic Oncology, 84, 404-412.	
/C.Y./	3	Saito et al., 2004, Correlation Between Responsiveness of Neoadjuvant Chemotherapy and Apoptosis-Associated Proteins for Cervical Adenocarcinoma, Gynecologic Oncology, 92, 284-292.	

Examiner	(Christopher Vaen/ (03/11/2009)	Date	00/11/0000
Signature	Aprilistopher raen/ (03/11/2009)	Considered	03/11/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.